Coma News and Research

RSS

Children more vulnerable to harmful effects of lead at age 6 than as toddlers

Contrary to prevailing assumptions, children are more vulnerable to the harmful effects of lead exposure at the age of 6 than they are in early childhood, according to a Cincinnati Children's Hospital Medical Center study to be presented May 4 at the annual meeting of the Pediatric Academic Societies in Honolulu.

30 Apr 2008

Three bitten by rabid dog in Britain

A dog imported into Britain from Sri Lanka has died of rabies but not before it had bitten three people.

28 Apr 2008

FSU research may speed new malaria treatments, vaccines for children

April 25 is World Malaria Day 2008 and despite the grim statistics out of Africa there's cause for celebration. Florida State University biologists have discovered an autoimmune-like response in blood drawn from malaria-infected African children that helps to explain why existing DNA-based anti-malaria vaccines have repeatedly failed to protect them.

23 Apr 2008

Orphan Europe files NDA with FDA for Carbaglu (carglumic acid)

Recordati announced the submission to the U.S. FDA by Orphan Europe (a Recordati group company) of an Original New Drug Application (NDA) for Carbaglu (carglumic acid).

21 Apr 2008

Social networking, malaria and philanthropy partnership

Philanthropy just got easier and a lot more accessible to the public thanks to the social networking power of the Internet and a ground-breaking partnership between a young British entrepreneur, a global health think tank and an African medical research institute.

20 Apr 2008

Shaken Baby Syndrome

Shaken Baby Syndrome (SBS), also known as childhood neurotrauma or inflicted traumatic brain injury, is the leading cause of death from childhood maltreatment.

10 Apr 2008

Type 1 diabetes study to improve the health of Wales

Swansea University researchers have been awarded more than £68,000 to investigate ways of reducing the risk of Type 1 diabetes patients developing potentially fatal hypoglycaemia (low blood glucose) during and after exercise.

9 Apr 2008

Experts warn, no Easter chocolate for pets!

Experts are warning pet owners not to give their dogs or cats chocolate over the Easter period.

19 Mar 2008

Large-scale study of traumatic brain injury

In a rare, large-scale study of traumatic brain injury (TBI) patients who span the full range of severity from mild to moderate and severe, Canadian researchers have found that the more severe the injury, the greater the loss of brain tissue, particularly white matter.

4 Mar 2008

AstraZeneca submits sNDA for SEROQUEL XR for treatment of major depressive disorder

AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.

1 Mar 2008

Lilly knocked back by FDA on Zyprexa for schizophrenia treatment

Eli Lilly and Company has received a not approvable letter from the U.S. Food and Drug Administration for Zyprexa long-acting injection (olanzapine LAI) for the treatment and maintenance treatment of schizophrenia in adults, the company announced.

28 Feb 2008

Two different neural pathways regulate loss and regain of consciousness during general anesthesia

University of Pennsylvania School of Medicine researchers have answered long-running questions about the way that anesthetics act on the body, by showing that the cellular pathway for emerging from anesthesia is different from the one that drugs take to put patients to sleep during operations.

14 Jan 2008

Dengue seen as potential threat to US public health

A disease most Americans have never heard of could soon become more prevalent if dengue, a flu-like illness that can turn deadly, continues to expand into temperate climates and increase in severity, according to a new commentary by Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and David M. Morens, M.D., Fauci's senior scientific advisor.

9 Jan 2008

AstraZeneca submits sNDAs for SEROQUEL XR for bipolar symptoms

AstraZeneca has announced that the company has submitted two separate supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) for once-daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder.

3 Jan 2008

New fast-acting antidote to cyanide poisoning

University of Minnesota Center for Drug Design and Minneapolis VA Medical Center researchers have discovered a new fast-acting antidote to cyanide poisoning.

28 Dec 2007

Discovery of potential oral treatment for diabetes

Research in the Department of Biology at the Faculty of Science and Science Education of the University of Haifa has discovered a substance that may become an oral treatment for diabetes and its complications.

28 Dec 2007

Sedative may have better outcomes than common medication for ICU patients on respirator

Intensive care unit patients on respirators who were sedated with the drug dexmedetomidine had more days alive without delirium or coma and better sedation compared to patients treated with the recommended drug lorazepam, according to a study in the December 12 issue of JAMA.

13 Dec 2007

Intensive care quality of sleep improved by new drug dexmedetomidine

A new sedative drug has been shown to improve the sleep quality and comfort levels of intensive care patients, compared to the most commonly-used medication, according to research published today in the journal JAMA.

13 Dec 2007

New genetic findings on malaria parasite

The malaria parasite has been studied for decades, but surprisingly, little is known about how it behaves in humans to cause disease.

29 Nov 2007

Sanofi Pasteur and Acambis to bring West Nile vaccine to market

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has signed an exclusive global collaboration agreement with Acambis plc, for the development and marketing of a West Nile vaccine to help fight against this serious, life-altering and potentially fatal disease.

14 Nov 2007